<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066520</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-ESP</org_study_id>
    <secondary_id>2008-007939-41</secondary_id>
    <nct_id>NCT01066520</nct_id>
  </id_info>
  <brief_title>TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain</brief_title>
  <acronym>TAASS</acronym>
  <official_title>A Randomized, Controlled, Multi-center Study on the Effectiveness of Traumeel S (Both Ointment and Gel) in Terms of Pain and Function Compared With a Topical NSAID in Athletes With Acute Ankle Sprain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biologische Heilmittel Heel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biologische Heilmittel Heel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy of Traumeel S (both ointment and
      gel) compared to another antiinflammatory drug called Diclofenac in patients with a sprained
      ankle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objective is the confirmatory proof of efficacy for Traumeel® S topical treatment, both
      ointment and gel, as compared to diclofenac topical treatment for patients with ankle sprain.
      In addition tolerability/safety of both drug preparations is to be compared, so that the
      benefit-risk relation can be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7</measure>
    <time_frame>From baseline (day 1) visit to day 7</time_frame>
    <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in absolute values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the Foot and Ankle Ability Measurement (FAAM), Activity of Daily Living Subscale (ADL) From Baseline to Day 7</measure>
    <time_frame>Day 1 to day 7</time_frame>
    <description>The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. The Foot and Ankle Ability Measure is a 29-item questionnaire divided into two subscales: the Foot and Ankle Ability Measure, 21-item Activities of Daily Living Subscale and the Foot and Ankle Ability Measure, 8-item Sports Subscale.
Each item is scored on a 5-point Likert scale (4 to 0) from 'no difficulty at all' (score 4), ´slight difficulty´, ´moderate difficulty´, éxtreme difficulty´ to 'unable to do' (score 0). Responses marked as ´not applicable´were not counted.
Item score totals, which range from 0 to 84 for the ADL subscale and 0 to 32 for the Sports subscale, were transformed to percentage scores. Higher scores represent higher levels of function for each subscale, with 100% representing no dysfunction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's Assessment of Ankle Pain (VAS)- Percentage Decrease on Day 7</measure>
    <time_frame>From baseline (day 1) visit to day 7</time_frame>
    <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in percentages.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FAAM ADL Subscale</measure>
    <time_frame>Day 1 to 4, 14, 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FAAM Sports Subscale</measure>
    <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swelling ('Figure-of-eight')</measure>
    <time_frame>Day 1 to 4,7,14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Assessment of Normal Function/Activity (5-point-scale)</measure>
    <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Normal Function (Training/Sports)</measure>
    <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Judgment of Efficacy</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Sprain of Ankle</condition>
  <arm_group>
    <arm_group_label>Traumeel S ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traumeel S ointment 2 g, 3 times daily topical during 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traumeel S gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traumeel S gel 2 g, 3 times daily topical during 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac gel 2 g, 3 times daily topical during 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traumeel S ointment</intervention_name>
    <description>2 g, 3 times daily topical during 14 days</description>
    <arm_group_label>Traumeel S ointment</arm_group_label>
    <other_name>Traumeel S ointment, Traumeel S gel, Diclofenac gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Traumeel S gel</intervention_name>
    <description>2 g, 3 times daily topical during 14 days</description>
    <arm_group_label>Traumeel S gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac gel</intervention_name>
    <description>2 g, 3 times daily topical during 14 days</description>
    <arm_group_label>Diclofenac gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Athletes with an acute unilateral ankle sprain of the lateral ligaments of the ankle
             joint both male and female

          -  Moderate (30-60 mm) to severe (&gt;60 mm) pain according to the patient's assessment of
             ankle pain visual analogue scale (VAS) on weight bearing, unable to perform normal
             training / sports activities

          -  18 - 40 years of age

          -  injury occurred within 24 hours of the first dose of study medication

          -  Willing and able to give written informed consent

          -  Available for the duration of the study

        Exclusion Criteria:

          -  Similar injury affecting the same joint within the past 6 months

          -  bilateral ankle injury

          -  bed rest, hospitalization, surgery use of a non-removable rigid cast

          -  Clinically important abnormality for screening laboratory tests

          -  Debilitating acute or chronic illness

          -  Use of corticosteroids in the previous 8 weeks, any analgesics in the previous 6
             hours, or 24 hours in case of long-acting NSAID, COX-2 specific inhibitors, or
             tramadol

          -  History of sensitivity to any component of the study drugs

          -  Unwilling or unable to comply with all the requirements of the protocol

          -  Participation in other studies within 4 weeks prior to study entry and or during the
             study participation

          -  Current substance or alcohol abuse that in the opinion of the investigator would
             interfere with compliance or with interpretation of the study result
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Gonzalez de Vega, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Coordinating Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MEDYR Medicina Deportiva y Rehabilitación</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12219/full</url>
    <description>Primary publication paper International Journal of Clinical Practice online</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <results_first_submitted>February 18, 2013</results_first_submitted>
  <results_first_submitted_qc>October 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ankle sprain</keyword>
  <keyword>traumeel</keyword>
  <keyword>diclofenac</keyword>
  <keyword>antiinflammatory</keyword>
  <keyword>time to normal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Initiation date stage I(299 patients):24.08.2009, completion date stage I: 19.01.2011 Initiation date stage II(150 patients): 04.03.2011, completion date stage II: 12.09.2011 The evaluation criteria have not been changed in the different stages. The interim analysis after Stage I re-confirmed the originally calculated sample size.</recruitment_details>
      <pre_assignment_details>Athletes of both sexes with acute unilateral sprain of the lateral ankle joint; 18 to 40 years of age; injury occurred within 24 hours of the first dose of study medication, with moderate (30-60mm) to severe (&gt;60mm) pain on weight bearing.420 of the enrolled 449 patients have been selected into the ITT population. 447 patients received treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Traumeel S Ointment</title>
          <description>Traumeel® S ointment, 2 g of ointment three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
        <group group_id="P2">
          <title>Traumeel S Gel</title>
          <description>Traumeel® S gel, 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
        <group group_id="P3">
          <title>Diclofenac Gel</title>
          <description>NSAID gel (Diclofenac 1%; standard brand), 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analyzed ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Traumeel S Ointment</title>
          <description>Traumeel S Ointment 2g, 3 times daily topical during 14 days</description>
        </group>
        <group group_id="B2">
          <title>Traumeel S Gel</title>
          <description>Traumeel S Gel 2g, 3 times daily topical during 14 days</description>
        </group>
        <group group_id="B3">
          <title>Diclofenac Gel</title>
          <description>Diclofenac Gel 2g, 3 times daily topical during 14 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="143"/>
            <count group_id="B2" value="140"/>
            <count group_id="B3" value="137"/>
            <count group_id="B4" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7</title>
        <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in absolute values.</description>
        <time_frame>From baseline (day 1) visit to day 7</time_frame>
        <population>Changes from baseline at day7: absolute values and in percentage. Primary analyses were based on the Intent-To-Treat sample. Only patients with intial VAS&lt;30 mm were excluded from the analysis set. Missing data were handled by the 'Last Observation Carried Forward' method.</population>
        <group_list>
          <group group_id="O1">
            <title>Traumeel S Ointment</title>
            <description>Traumeel® S ointment, 2 g of ointment three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O2">
            <title>Traumeel S Gel</title>
            <description>Traumeel® S gel, 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O3">
            <title>Diclofenac Gel</title>
            <description>NSAID gel (Diclofenac 1%; standard brand), 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7</title>
          <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in absolute values.</description>
          <population>Changes from baseline at day7: absolute values and in percentage. Primary analyses were based on the Intent-To-Treat sample. Only patients with intial VAS&lt;30 mm were excluded from the analysis set. Missing data were handled by the 'Last Observation Carried Forward' method.</population>
          <units>Absolute value units on a scale VAS</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.00" lower_limit="-45.40" upper_limit="-23.70"/>
                    <measurement group_id="O2" value="-37.10" lower_limit="-50.00" upper_limit="-27.30"/>
                    <measurement group_id="O3" value="-37.10" lower_limit="-47.40" upper_limit="-26.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of the Foot and Ankle Ability Measurement (FAAM), Activity of Daily Living Subscale (ADL) From Baseline to Day 7</title>
        <description>The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. The Foot and Ankle Ability Measure is a 29-item questionnaire divided into two subscales: the Foot and Ankle Ability Measure, 21-item Activities of Daily Living Subscale and the Foot and Ankle Ability Measure, 8-item Sports Subscale.
Each item is scored on a 5-point Likert scale (4 to 0) from ‘no difficulty at all’ (score 4), ´slight difficulty´, ´moderate difficulty´, éxtreme difficulty´ to ‘unable to do’ (score 0). Responses marked as ´not applicable´were not counted.
Item score totals, which range from 0 to 84 for the ADL subscale and 0 to 32 for the Sports subscale, were transformed to percentage scores. Higher scores represent higher levels of function for each subscale, with 100% representing no dysfunction.</description>
        <time_frame>Day 1 to day 7</time_frame>
        <population>Changes to Baseline: absolute values. Primary analyses were based on the Intent-To-Treat sample. Only patients with intial VAS&lt;30 mm were excluded from the analysis set. Missing data were handled by the ‘Last Observation Carried Forward’ method.</population>
        <group_list>
          <group group_id="O1">
            <title>Traumeel S Ointment</title>
            <description>Traumeel® S ointment, 2 g of ointment three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O2">
            <title>Traumeel S Gel</title>
            <description>Traumeel® S gel, 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O3">
            <title>Diclofenac Gel</title>
            <description>NSAID gel (Diclofenac 1%; standard brand), 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
        </group_list>
        <measure>
          <title>Change of the Foot and Ankle Ability Measurement (FAAM), Activity of Daily Living Subscale (ADL) From Baseline to Day 7</title>
          <description>The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments. The Foot and Ankle Ability Measure is a 29-item questionnaire divided into two subscales: the Foot and Ankle Ability Measure, 21-item Activities of Daily Living Subscale and the Foot and Ankle Ability Measure, 8-item Sports Subscale.
Each item is scored on a 5-point Likert scale (4 to 0) from ‘no difficulty at all’ (score 4), ´slight difficulty´, ´moderate difficulty´, éxtreme difficulty´ to ‘unable to do’ (score 0). Responses marked as ´not applicable´were not counted.
Item score totals, which range from 0 to 84 for the ADL subscale and 0 to 32 for the Sports subscale, were transformed to percentage scores. Higher scores represent higher levels of function for each subscale, with 100% representing no dysfunction.</description>
          <population>Changes to Baseline: absolute values. Primary analyses were based on the Intent-To-Treat sample. Only patients with intial VAS&lt;30 mm were excluded from the analysis set. Missing data were handled by the ‘Last Observation Carried Forward’ method.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.20" lower_limit="16.70" upper_limit="35.70"/>
                    <measurement group_id="O2" value="26.20" lower_limit="16.70" upper_limit="36.90"/>
                    <measurement group_id="O3" value="25.00" lower_limit="14.60" upper_limit="34.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FAAM ADL Subscale</title>
        <time_frame>Day 1 to 4, 14, 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FAAM Sports Subscale</title>
        <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swelling ('Figure-of-eight')</title>
        <time_frame>Day 1 to 4,7,14</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Assessment of Normal Function/Activity (5-point-scale)</title>
        <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Normal Function (Training/Sports)</title>
        <time_frame>Day 1 to 4, 7, 14, 42</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Judgment of Efficacy</title>
        <time_frame>Day 14</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient's Assessment of Ankle Pain (VAS)- Percentage Decrease on Day 7</title>
        <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in percentages.</description>
        <time_frame>From baseline (day 1) visit to day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Traumeel S Ointment</title>
            <description>Traumeel® S ointment, 2 g of ointment three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O2">
            <title>Traumeel S Gel</title>
            <description>Traumeel® S gel, 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
          <group group_id="O3">
            <title>Diclofenac Gel</title>
            <description>NSAID gel (Diclofenac 1%; standard brand), 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Assessment of Ankle Pain (VAS)- Percentage Decrease on Day 7</title>
          <description>Pain evaluated by a 100 mm visual analogue scale (VAS) where 0 means no pain and 100 means the highest, unbearable pain. The absolute values of VAS have been the basis of analysis.
The highest is the change in negative, the better are the results in percentages.</description>
          <units>Percentage change in scale VAS</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.55" lower_limit="-85.70" upper_limit="-42.90"/>
                    <measurement group_id="O2" value="-71.10" lower_limit="-84.85" upper_limit="-48.40"/>
                    <measurement group_id="O3" value="-68.90" lower_limit="-83.60" upper_limit="-48.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety information was collected for the whole duration of the trial from 24.08.2009 (FPI) to 12.09.2011 (LPO)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Traumeel S Ointment</title>
          <description>Traumeel® S ointment, 2 g of ointment three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
        <group group_id="E2">
          <title>Traumeel S Gel</title>
          <description>Traumeel® S gel, 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
        <group group_id="E3">
          <title>Diclofenac Gel</title>
          <description>NSAID gel (Diclofenac 1%; standard brand), 2 g of gel three times daily for 14 days, to sufficiently cover the area of the lesion, gently rubbing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Nasopharingitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypoasthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharingeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Istvan Zatik</name_or_title>
      <organization>Biologische Heilmittel Heel GmbH</organization>
      <phone>+4972215013192</phone>
      <email>istvan.zatik@heel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

